David Sallman, MD, assistant member in the Department of Malignant Hematology at Moffitt Cancer Center, discusses molecular testing and how it has transformed the care of patients with AML. He discusses the need for risk assessment and how next-generation sequencing can be used to personalize management of each patient. Dr Sallman notes that it is important to assess for FLT3 and a next-generation sequencing panel at diagnosis and at relapse or refractory disease time points.